Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Chronic Myeloid Leukemia
Hehlmann
Editore
Springer
Anno
2021
Pagine
273
ISBN
9783030719159
80,00 €
DA SCONTARE
This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.
-
Cytogenetics of Chronic Myeloid Leukemia (CML)
Pages 1-16
Balk, Bettina (et al.)
-
The Biology and Pathogenesis of Chronic Myeloid Leukaemia
Pages 17-36
Shanmuganathan, Naranie (et al.)
-
Epidemiology of Chronic Myeloid Leukaemia
Pages 37-48
Höglund, Martin (et al.)
-
Imatinib: The First-Line CML Therapy
Pages 49-59
Fava, Carmen (et al.)
-
CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors
Pages 61-76
Lovell, Alexandra (et al.)
-
Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Pages 77-91
Rea, Delphine
-
Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
Pages 93-104
Muluneh, Benyam (et al.)
-
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia: 2021 Update
Pages 105-117
Salmon, Matthew (et al.)
-
Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death
Pages 119-143
Pfirrmann, Markus (et al.)
-
A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
Pages 145-158
Gugliotta, Gabriele (et al.)
-
The Role of Hematopoietic Stem Cell Transplantation in CML
Pages 159-178
Apperley, Jane F. (et al.)
-
CML End Phase and Blast Crisis: Implications and Management
Pages 179-196
Hehlmann, Rüdiger (et al.)
-
The Interferon-Alpha Revival in CML
Pages 197-226
Talpaz, Moshe (et al.)
-
Managing Pregnancy in Chronic Myeloid Leukaemia
Pages 227-244
Abruzzese, Elisabetta (et al.)
-
Response-Related Predictors of Survival and of Treatment-Free Remission in CML
Pages 245-264
Branford, Susan (et al.)
-
Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response
Pages 265-273
Saußele, Susanne (et al.)
